Strategic Transformation of the Market of HCV Treatments
Status:
Active, not recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase II/III, multicenter, multi-country, trial to assess the efficacy, safety,
tolerance and pharmacokinetics of sofosbuvir plus ravidasvir for the treatment of HCV
infection.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Drugs for Neglected Diseases
Collaborators:
Ministry of Health, Malaysia Ministry of Health, Thailand National Science and Technology Development Agency, Thailand